FDA Measures Naloxone Price Trend In Considering Wider Availability
This article was originally published in The Tan Sheet
Executive Summary
Even though FDA cannot consider drug pricing, it gives research of naloxone sales to inform workshop on uptake and use. Amphastar’s naloxone prices are being scrutinized by state officials and a House member.
You may also be interested in...
Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
FDA 'complete response' letter follows advisory committee's conclusion that the current naloxone approval standard is inadequate.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.